10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Kezar Life Sciences, which is developing selective immunoproteasome inhibitors to treat autoimmune diseases, raised $75 million in a slightly upsized IPO by offering 5 million shares at $15, the midpoint of the $14 to $16 range. The company originally planned to...read more
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Kezar Life Sciences, which is developing small molecule therapeutics to treat autoimmune diseases and cancer, announced terms for its IPO on Friday. The San Fancisco, CA-based company plans to raise $70 million by offering 4.7 million shares at a price...read more
US IPO Weekly Recap: Biotechs boom in a 13-deal torrent
10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Kezar Life Sciences prices slightly upsized IPO at $15 midpoint
Kezar Life Sciences, which is developing selective immunoproteasome inhibitors to treat autoimmune diseases, raised $75 million in a slightly upsized IPO by offering 5 million shares at $15, the midpoint of the $14 to $16 range. The company originally planned to...read more
US IPO Week Ahead: Health care deals lead 11-IPO week
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Autoimmune disease biotech Kezar Life Sciences sets terms for $70 million IPO
Kezar Life Sciences, which is developing small molecule therapeutics to treat autoimmune diseases and cancer, announced terms for its IPO on Friday. The San Fancisco, CA-based company plans to raise $70 million by offering 4.7 million shares at a price...read more